OncoMatch/Clinical Trials/NCT05656573
CART-PSMA Cells for Advanced Prostate Cancer
Is NCT05656573 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CART-PSMA cells for prostate cancer.
Treatment: CART-PSMA cells — This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 overexpression (as demonstrated by immunohistochemistry analysis or other methods)
Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: gene therapy
Patients who are already undergoing other gene therapy
Cannot have received: cell therapy
Patients who are already undergoing other ... cell therapy
Cannot have received: other clinical drug trials
Patients who are already undergoing other clinical drug trials
Lab requirements
Blood counts
hemoglobin concentration ≥80g/L
Kidney function
serum creatinine < 2.0 mg/dl
Liver function
ALT < 3x ULN, AST < 3x ULN, serum bilirubin and alkaline phosphatase < 2x ULN
Cardiac function
left ventricular ejection fraction (LVEF) ≥50%
Adequate liver function, specifically alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN), aspartate transferase (AST)< 3 times of ULN, serum bilirubin and alkaline phosphatase < 2 times of ULN. Adequate renal function, specifically serum creatinine < 2.0 mg/dl. Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%. Hemoglobin concentration ≥80g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05656573 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, cell therapy, other clinical drug trials disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger and at least 35 years old.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages